Arcadia Biosciences, Inc.
RKDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.03 | -0.05 |
| FCF Yield | -119.48% | -395.16% | -216.23% | -121.43% |
| EV / EBITDA | -0.53 | 0.12 | 0.89 | 0.14 |
| Quality | ||||
| ROIC | -32.45% | -81.77% | -72.65% | -86.60% |
| Gross Margin | 41.27% | 38.09% | 1.55% | -28.44% |
| Cash Conversion Ratio | 2.23 | 1.09 | 0.90 | 1.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.06% | -13.07% | -2.62% | 79.67% |
| Free Cash Flow Growth | 36.97% | -8.90% | 47.72% | 17.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.41 | 1.36 | 1.09 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,776.30 |
| Efficiency | ||||
| Inventory Turnover | 3.28 | 1.69 | 3.81 | 1.96 |
| Cash Conversion Cycle | 246.80 | 163.17 | 106.80 | 200.42 |